These combined studies confirm that SL1026 is a potent antagonist of the IL-6 signaling pathway and represents a new class of drug candidate for the treatment of IL-6-mediated diseases including RA, inflammation, and cancer. This evidence concerns the gene IL6 and rheumatoid arthritis.